characteristic | Training cohort(n = 1228) | Validation cohort(n = 359) | ||
---|---|---|---|---|
Number of patients | Composition ratio (%) | Number of patients | Composition ratio (%) | |
Sex | ||||
Male | 845 | 68.8% | 258 | 71.9% |
Female | 383 | 31.2% | 101 | 28.1% |
Age | ||||
< 60 years | 415 | 33.8% | 111 | 30.9% |
≥ 60 years | 813 | 66.2% | 248 | 69.1% |
NLR | ||||
< 3.29 | 864 | 70.4% | 252 | 70.2%% |
≥ 3.29 | 364 | 29.6% | 107 | 29.8%% |
NMR | ||||
< 12.77 | 1013 | 82.5% | 289 | 80.5% |
≥ 12.77 | 215 | 17.5% | 70 | 19.5% |
LMR | ||||
< 2.95 | 421 | 34.3% | 126 | 35.1% |
≥ 2.95 | 807 | 65.7% | 233 | 64.9% |
RDW | ||||
< 15.05% | 786 | 64% | 234 | 65.2% |
≥ 15.05% | 442 | 36% | 125 | 34.8% |
PDW | ||||
< 13.65% | 1103 | 89.8% | 324 | 90.3% |
≥ 13.65% | 125 | 10.2% | 35 | 9.7% |
Tumor location | ||||
Upper | 49 | 4.0% | 12 | 3.3% |
Middle | 892 | 72.6% | 258 | 71.9% |
Lower | 287 | 23.4% | 89 | 24.8% |
Depth of tumor invasion | ||||
pT1 | 106 | 8.6% | 27 | 7.5% |
pT2 | 301 | 24.5% | 87 | 24.2% |
pT3 | 793 | 64.6% | 230 | 64.1% |
pT4 | 28 | 2.3% | 15 | 4.2% |
Lymph node metastasis | ||||
pN0 | 502 | 40.9% | 149 | 41.5% |
pN1 | 502 | 40.9% | 134 | 37.3% |
pN2 | 224 | 18.2% | 76 | 21.2% |
Differentiation | ||||
G1 | 61 | 5% | 15 | 4.2% |
G2 | 693 | 56.4% | 210 | 58.5% |
G3 | 474 | 38.6% | 134 | 37.3% |
Stage | ||||
I | 98 | 8% | 27 | 7.5% |
II | 506 | 41.2% | 141 | 39.3% |
III | 624 | 50.8% | 191 | 53.2% |